Excision

Philadelphia, United States Founded: 2015 • Age: 11 yrs
CRISPR-based therapies are developed to cure viral infectious diseases.

About Excision

Excision is a Healthcare company based in Philadelphia (United States) founded in 2015. CRISPR-based therapies are developed to cure viral infectious diseases. Excision has raised $70.74 million across 3 funding rounds from investors including HHS, Norwest Venture Partners and GreatPoint Ventures. Its chief executive, as recorded, is Daniel Dornbusch. Excision offers products and services including CRISPR Therapy for HIV, CRISPR Therapy for HSV, and CRISPR Therapy for Hepatitis B. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral. Its legal entity is Excision BioTherapeutics, Inc. Its competitors include Moderna, Adaptive Biotechnologies and Novavax; 2 of its 3 listed competitors have raised funding.

Company details

Excision BioTherapeutics, Inc., is a biotechnology company developing CRISPR-based therapies to cure viral infectious diseases. Excision is focused on improving the lives of chronically ill patients by eliminating viral genomes from infected individuals. By using CRISPR in unique ways, the Company has already demonstrated the first functional cure for HIV in animals. Excision is developing technologies and IP developed at Temple University and U.C. Berkeley. Excision is located in San Francisco, California and is supported by ARTIS Ventures, GreatPoint Ventures, Norwest Venture Partners, Adjuvant Capital, Cota Capital, WRVI Capital, IndusAge Partners, Loreda Holdings, Olive Tree, Anzu Partners, SilverRidge Venture Partners, Oakhouse Ventures, and Gaingels.

  • Headquarters Philadelphia, United States
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website excision.bio
  • Social LinkedIn X Facebook Instagram
  • Legal Name Excision Biotherapeutics, Inc.
Operational Areas
Key Metrics
  • Total Equity Funding
    $70.74M (USD)

    in 3 rounds

  • Latest Funding Round
    $60.74M (USD), Series A

    Feb 2021

  • Investors
    HHS

    & 9 more

Products & Services of Excision

Excision offers a comprehensive portfolio of products and services, including CRISPR Therapy for HIV, CRISPR Therapy for HSV, and CRISPR Therapy for Hepatitis B.

CRISPR Therapy for HIV
Gene Therapy

Edits viral DNA to eliminate HIV in infected cells.

CRISPR Therapy for HSV
Gene Therapy

Targets herpes simplex viruses for potential cure.

CRISPR Therapy for Hepatitis B
Gene Therapy

Disrupts hepatitis B viral DNA to reduce infection.

Funding Insights of Excision

Excision has successfully raised a total of $70.74M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $60.74 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $70.74M
  • Total Rounds 3
  • Last Round Series A β€” $60.74M
  • First Round $10M

    (Sep 2017)

  • Investors Count 10

All 3 funding rounds of Excision with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Feb 2021$60.74MSeries A–GreatPoint Ventures, Celesta Capital
Jun 2019$217,484Grant––
Sep 2017$10MSeed–Artis Ventures
–
Valuation history

10 investors in total: 10 institutional.

Investors in Excision

Excision has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Norwest Venture Partners and GreatPoint Ventures.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Venture capital firm focused on early-stage big data, health tech, AI, food tech, and multiple sectors
gpv.comSan Francisco, United States
Early-stage startups are invested in by Artis Ventures.
av.coSan Francisco, United States
Venture capital is deployed for global health technology innovations.
adjuvantcapital.comNew York City, USA
Venture capital and growth equity firm providing investments and resources to entrepreneurs in various sectors.
1961nvp.comMenlo Park, United States
Investments are made in industrial and life sciences technology companies.
anzupartners.comWashington, Dc, United States
Provider of a venture capital firm that invests in technology and life sciences companies
olivetreecapital.comBoston, United States
Stage-agnostic venture capital investments are focused on US sectors.
cotacapital.comSan Francisco, United States
Early-stage tech investments are made in India, US, and UK.
indusage.comBengaluru, India
Venture capital firm focused on multiple sectors
celesta.vcSan Francisco, United States
Public health and human services are overseen by HHS.
1953hhs.gov
Premium access

Investor details for Excision

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Excision

42 people are tracked at Excision (12 in leadership, 21 in board & advisors, 9 in team).

NameRoleGroup
Daniel Dornbusch
CEOLeadership
Salvatore Amato
Senior Director, FinanceLeadership
Qin Xiang
Director, Analytical Development & QCLeadership
Elvin Ruan
Senior Director, Genome EditingLeadership
Ryo Takeuchi
Director, Genome EditingLeadership
Franz Gerner
CTOLeadership
TJ Cradick
Chief Scientific OfficerLeadership
Ann Branca
VP, Clinical Operations in Clinical Development & OperationsLeadership
Christine Silverstein
CFOLeadership
Meriza Viray
Director, Clinical OperationsLeadership
Helen Zhao
Senior Director, Project ManagementLeadership
Nadia Amrani
Associate Director, Genome EditingLeadership
Toni Cathomen
Scientific Advisory Board MemberBoard & advisors
Joseph Berger
Scientific Advisory Board MemberBoard & advisors
Kenneth L. Tyler
Scientific Advisory Board MemberBoard & advisors
John Baxter
Scientific Advisory Board MemberBoard & advisors
David Clifford
Scientific Advisory Board MemberBoard & advisors
Timothy M. Block
Scientific Advisory BoardBoard & advisors
Vasudev Bailey
DirectorBoard & advisors
Keith Jerome
Scientific Advisory Board MemberBoard & advisors

22 more people are available in the full profile.

Premium access

Complete people profiles for Excision

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Excision

3 dated milestones of Excision across 6 years, from founding to its latest funding, stage changes and deals.

  1. Founded Excision is founded.
  2. Funding First funding round of $10.0M.
  3. Funding Latest funding round, Series A, of $60.7M.

Competitors of Excision

Excision has 3 listed competitors in our database, 2 of them funded. They include Moderna, Adaptive Biotechnologies and Novavax.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
modernatx.com2010Cambridge, United States$2.78B1,312
mRNA-based therapeutics for diseases including cancer and infections are developed.
adaptivebiotech.com2009Seattle, United States$419.15M609
Clinical diagnostics and drug discovery for immune diseases are provided.
novavax.com1987Gaithersburg, United States184
Novel vaccines are developed using nanoparticle and matrix adjuvant technology.
Premium access

Detailed competitors of Excision

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Excision

The website of Excision (excision.bio) receives about 2.4K visits a month.

  • Monthly visits
    2.4K

    ▼ 55.4% vs previous month

Similar websites

Websites whose visitors overlap most with Excision. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
r2mpharma.com
100%
2.9K#4,331,217View details
aligos.com
98%
3.4K#3,982,602View details
astellasgenetherapies.com
98%
1KView details
quantatx.com
96%
3.1K#5,909,422View details
shennonbio.com
96%
View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 30 similar websites and full traffic analytics for Excision

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 30 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Infectious Diseases

3 companies that operate in the same segment as Excision (Infectious Diseases) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Developer of molecular diagnostic testing solutions
1996Sunnyvale, California, United StatesUSD 19.1 MUSD 87.11 M4,647
Therapeutics for drug-resistant bacterial infections are developed.
2013Cambridge, Massachusetts, United StatesUSD 114.7 MUSD 59.62 M32
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Excision

Premium access

Complete news archive for Excision

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Excision

Excision was founded in 2015 and raised its 1st funding round 2 years after it was founded.

Excision is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.

Daniel Dornbusch is the CEO of Excision, as recorded in our data.

Excision is a funded company, having raised a total of $70.74M across 3 funding rounds to date. The company's 1st funding round was a Seed of $10M, raised on Sep 2017.

Excision BioTherapeutics, Inc., is a biotechnology company developing CRISPR-based therapies to cure viral infectious diseases. Excision is focused on improving the lives of chronically ill patients by eliminating viral genomes from infected individuals. By using CRISPR in unique ways, the Company has already demonstrated the first functional cure for HIV in animals. Excision is developing technologies and IP developed at Temple University and U.C. Berkeley. Excision is located in San Francisco, California and is supported by ARTIS Ventures, GreatPoint Ventures, Norwest Venture Partners, Adjuvant Capital, Cota Capital, WRVI Capital, IndusAge Partners, Loreda Holdings, Olive Tree, Anzu Partners, SilverRidge Venture Partners, Oakhouse Ventures, and Gaingels.

Excision's top competitors include Moderna, Adaptive Biotechnologies and Novavax.

Excision offers CRISPR Therapy for HIV, CRISPR Therapy for HSV, and CRISPR Therapy for Hepatitis B.

Excision has 10 investors. Key investors include HHS, Norwest Venture Partners, GreatPoint Ventures, Artis Ventures, and Adjuvant Capital.

Excision operates through Excision Biotherapeutics, Inc..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available